Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 49 Stocks Moving In Wednesday's Mid-Day Session

Gainers

Losers

Also check this out Bitcoin Tops $18,000; GMX, Dogecoin Among Top Losers.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

Gainers

Crown ElectroKinetics Corp. (NASDAQ:CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) shares jumped 140% to $0.6041 after the company entered into a definitive merger agreement with GRI Bio.
Immix Biopharma, Inc. (NASDAQ:IMMX) jumped 46% to $2.1695 after the company announced it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 with 85% ORR and 71% CR/sCR at the therapeutic dose from the first 20 patients in an ongoing phase 1b relapsed/refractory multiple myeloma ongoing clinical trial.
Senti Biosciences, Inc. (NASDAQ:SNTI) rose 45% to $2.09 after dipping more than 21% on Tuesday.
Avidity Biosciences, Inc. (NASDAQ:RNA) shares climbed 44.3% to $15.84 after the company announced AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial demonstrating the first-ever successful targeted delivery of RNA into muscle.
BIMI International Medical, Inc. (NASDAQ:BIMI) gained 28.1% to $2.6649. BIMI reported entry into a material definitive agreement for the acquisition of Wuzhou Qiangsheng Hospital Co., Ltd., Suzhou Eurasia Hospital Co., Ltd. and Yunan Yuxi Minkang Hospital Co., Ltd.
Wave Life Sciences Ltd. (NASDAQ:WVE) gained 21.1% to $5.80. SVB Leerink maintained WAVE Life Sciences with a Market Perform and raised the price target from $2 to $7.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares gained 21.4% to $31.38 after the company announced results from the Phase 1 clinical trial evaluating KT-474 in patients with HS and AD and Sanofi's decision to advance KT-474 into Phase 2 clinical trials.
Aspen Group, Inc. (NASDAQ:ASPU) gained 17.4% to $0.41 after reporting strong quarterly sales.
REV Group, Inc. (NYSE:REVG) jumped 17.2% to $15.57 as the company reported a fourth-quarter FY22 sales growth of 5.7% year-over-year to $623.6 million, beating the consensus of $595 million.
Nuvve Holding Corp. (NASDAQ:NVVE) gained 16.9% to $0.7477.
Meiwu Technology Company Limited (NASDAQ:WNW) jumped 16.3% to $2.14.
United Insurance Holdings Corp. (NASDAQ:UIHC) jumped 16.2% to $0.5578.
Dyne Therapeutics, Inc. (NYSE:DYN) jumped 14.7% to $14.00.
Sio Gene Therapies Inc. (NASDAQ:SIOX) gained 14.7% to $0.3537.
Otonomy, Inc. (NASDAQ:OTIC) jumped 14.4% to $0.1399.
Harmonic Inc. (NASDAQ:HLIT) gained 12.9% to $14.86
Happiness Development Group Limited (NASDAQ:HAPP) rose 12.9% to $3.9973after surging over 10% on Tuesday.
Carvana Co. (NYSE:CVNA) gained 12.8% to $5.45.
Appreciate Holdings, Inc. (NASDAQ:SFR) jumped 12.4% to $1.90.
Harrow Health, Inc. (NASDAQ:HROW) surged 11.9% to $12.43. Harrow Health entered a binding agreement to acquire the exclusive U.S. commercial rights to five FDA‑approved ophthalmic products from Novartis.
Mullen Automotive, Inc. (NASDAQ:MULN) jumped 10% to $0.2354. Mullen Automotive partnered with Loop Global to deploy EV charging solutions, including public DC fast charging network and residential offerings.
QualTek Services Inc. (NASDAQ:QTEK) gained 9.3% to $0.5463.
Cytokinetics, Incorporated (NASDAQ:CYTK) jumped 7.6% to $41.27. The FDA's Cardiovascular and Renal Drugs Advisory Committee voted 8-3 against the approval of Cytokinetics heart failure drug, omecamtiv mecarbil.
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) gained 6.3% to $2.02. Processa Pharmaceuticals said PCS12852 successfully improves the clinical symptoms associated with gastroparesis in Phase 2A trial.

Losers

Drive Shack Inc. (NYSE:DS) fell 55.3% to $0.2126. The company announced its intention to voluntarily delist from the NYSE and to deregister its common stock.
ZyVersa Therapeutics Inc (NASDAQ:ZVSA) dipped 36.5% to $4.76.
Netcapital Inc. (NASDAQ:NCPL) shares dipped 33.3% to $1.47 after the company announced pricing of a public offering.
OpGen, Inc. (NASDAQ:OPGN) fell 29.8% to $0.1621. OpGen shares jumped around 85% on Tuesday after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
Puhui Wealth Investment Management Co., Ltd. (NASDAQ:PHCF) fell 25.7% to $2.95.
Kaspien Holdings Inc. (NASDAQ:KSPN) fell 24.2% to $0.7490 after the company reported a wider Q3 loss.
Versus Systems Inc. (NASDAQ:VS) declined 23.1% to $0.5998.
SeqLL Inc. (NASDAQ:SQL) dropped 21.7% to $0.3789.
Vincerx Pharma, Inc. (NASDAQ:VINC) declined 21.7% to $0.83.
Avadel Pharmaceuticals plc (NASDAQ:AVDL) fell 20.9% to $6.52.
Getaround, Inc. (NYSE:GETR) fell 20.4% to $1.09.
Bit Brother Limited (NASDAQ:BTB) dropped 20% to $0.4238 after the company announced a 1-for-15 reverse share split.
Oriental Culture Holding LTD (NASDAQ:OCG) declined 18.8% to $0.71.
Yumanity Therapeutics, Inc. (NASDAQ:YMTX) fell 16.8% to $1.6886. Yumanity Therapeutics recently declared a special dividend in connection with the proposed asset sale to Janssen and merger with Kineta.
Baudax Bio, Inc. (NASDAQ:BXRX) fell 16.6% to $2.5925.
Summit Therapeutics Inc. (NASDAQ:SMMT) fell 16.4% to $3.2691.
Bright Health Group, Inc. (NYSE:BHG) dropped 16% to $0.6137. Goldman Sachs, on Tuesday, downgraded Bright Health from Neutral to Sell.
Arqit Quantum Inc. (NASDAQ:ARQQ) fell 14.7% to $5.33 after the company reported FY22 results and filed for a mixed shelf of up to $100 million..
Charter Communications, Inc. (NASDAQ:CHTR) fell 13.3% to $340.65 after it communicated an increase in 2023 capital expenditures at its analyst day held on Tuesday.
Rubicon Technology, Inc. (NASDAQ:RBCN) shares fell 13.1% to $1.5814. Rubicon Technology announced voluntary delisting from the Nasdaq.
Nexalin Technology, Inc. (NASDAQ:NXL) fell 11.1% to $1.7250.
Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) dropped 11% to $12.32.
LAVA Therapeutics N.V. (NASDAQ:LVTX) fell 9.4% to $4.20. LAVA Therapeutics announced updated data from the Phase 1/2a clinical trial of LAVA-051 at the 64th American Society of Hematology Annual Meeting and Exposition.
Panbela Therapeutics, Inc. (NASDAQ:PBLA) fell 7.1% to $0.1327 after gaining around 53% on Tuesday. Panbela received EMA opinion on orphan designation for Ivospemin in combination with Gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.